FDA Approves Hovilpri: A New Oral Treatment Option for Difficult-to-Treat Herpes Simplex Virus Infections
The FDA has approved Hovilpri (pritelivir) for refractory mucocutaneous herpes simplex virus infections in immunocompromised adults. Discover the clinical trial results, potential benefits, and important safety considerations.
Introduction
The treatment landscape for herpes simplex virus (HSV) infections has reached an important milestone following the US Food and Drug Administration's (FDA) approval of Hovilpri (pritelivir). Announced by Asahi Kasei Therapeutics on October 10, 2026, the approval introduces a new oral treatment option for immunocompromised adults experiencing mucocutaneous HSV lesions that do not respond adequately to certain established antiviral medicines.
Hovilpri offers a different mechanism of action from conventional antiviral treatments and represents a significant development in the management of difficult-to-treat HSV infections. Its approval is particularly relevant for patients whose weakened immune systems increase their risk of persistent infections and complications.
The decision is supported by results from the Phase 3 PRIOH-1 clinical trial, which demonstrated improved lesion healing compared with investigator-selected treatments.
What Is Hovilpri and How Does It Work?
Hovilpri contains pritelivir, an oral antiviral medicine classified as a helicase-primase inhibitor. It is indicated for immunocompromised adults with mucocutaneous lesions caused by HSV infection that is refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir.
These established antiviral medicines belong to a different drug class known as nucleoside analogues. Their antiviral activity depends on processes involving the viral thymidine kinase enzyme. Changes in this enzyme can contribute to reduced susceptibility to treatment in some HSV infections.
Pritelivir works differently by targeting the viral helicase-primase complex, which is essential for viral DNA replication. This alternative mechanism provides a treatment approach for eligible patients whose infections remain difficult to manage with conventional antiviral therapies.
According to Asahi Kasei Therapeutics, Hovilpri is active against HSV-1 and HSV-2, including certain strains resistant to nucleoside analogues and foscarnet.
Why Is This FDA Approval Important?
HSV infections are common and often cause no symptoms or only mild illness. However, the clinical picture can be different for people with weakened immune systems.
Immunocompromised individuals, including organ transplant recipients, people living with HIV, and patients receiving treatment for certain cancers or autoimmune and inflammatory conditions, may experience more frequent or severe HSV episodes.
In some cases, lesions persist despite antiviral treatment. These refractory infections can cause prolonged discomfort and create additional challenges for patients and healthcare professionals.
Treatment options may also be limited when conventional antiviral medicines are ineffective. Alternative treatments can require intravenous administration, adding complexity to treatment delivery and patient management.
Hovilpri provides an oral option for eligible adults in this setting. Its approval also marks the introduction of an HSV therapy with a novel mechanism of action, representing an important development after a long period without a newly approved treatment approach of this kind.
However, the medicine is not intended for every person with HSV. Its approved indication specifically covers immunocompromised adults with refractory mucocutaneous HSV lesions.
What Did the Phase 3 PRIOH-1 Trial Show?
The FDA approval was supported by Part C of the PRIOH-1 Phase 3 trial, a randomized, open-label, comparator-controlled study involving 101 immunocompromised adults with refractory HSV infections.
Participants received oral pritelivir or an investigator-selected treatment. The comparison treatments included intravenous foscarnet, intravenous or topical cidofovir, and topical imiquimod. Treatment lasted up to 28 days, with the possibility of extension to 42 days when lesions were improving.
The primary efficacy endpoint focused on complete lesion healing by Day 28.
The results showed that:
- 63% of participants receiving Hovilpri achieved complete lesion healing by Day 28.
- 34% of participants receiving investigator-selected treatment achieved complete lesion healing by Day 28.
- The adjusted treatment difference was 28.4 percentage points, with a 95% confidence interval of 9.6 to 47.3 and a p-value of 0.0047.
By Day 42, the observed response rates were 82% for Hovilpri and 42% for investigator-selected treatment.
These findings indicate that Hovilpri demonstrated statistically significant superiority for lesion healing in the studied population. Nevertheless, individual outcomes can vary, and trial results do not guarantee that every patient will respond similarly.
Safety Profile and Important Considerations
Safety remains an important part of treatment selection, particularly for patients managing complex medical conditions and multiple medications.
In Part C of PRIOH-1, adverse reactions were reported in 22% of participants receiving Hovilpri, compared with 54% receiving investigator-selected treatment. Discontinuations due to adverse drug reactions occurred in 2% and 20% of participants, respectively.
Headache was the most commonly reported adverse reaction associated with Hovilpri, occurring in 6% of participants, compared with 4% in the comparator group.
The prescribing information also highlights important drug interaction considerations.
Certain acid-reducing medicines can lower pritelivir exposure and potentially reduce its effectiveness. The prescribing information advises avoiding concomitant use with esomeprazole or rabeprazole, as well as certain higher doses of other proton pump inhibitors. Specific timing requirements apply to H2-receptor antagonists and antacids.
Additionally, pritelivir inhibits breast cancer resistance protein (BCRP). Taking it alongside medicines that are BCRP substrates may increase their concentrations and the risk of adverse reactions.
Patients should discuss all prescription medicines, over-the-counter products, and supplements with their healthcare professional before starting treatment. Treatment decisions and medication adjustments should be guided by the prescribing information and an appropriately qualified clinician.
Availability and What Happens Next?
Asahi Kasei Therapeutics expects Hovilpri to become available in the United States before the end of 2026. Healthcare professionals can consult the company's official Hovilpri healthcare provider website for further information.
The approval represents progress in addressing an unmet medical need for immunocompromised adults with treatment-refractory HSV infections. Further clinical experience will help healthcare professionals understand how the medicine fits into routine treatment decisions and individual patient care.
Conclusion
The FDA approval of Hovilpri introduces a new oral treatment option for immunocompromised adults with mucocutaneous HSV lesions that have not responded adequately to specified conventional antiviral therapies.
The PRIOH-1 trial demonstrated higher complete lesion healing rates with pritelivir than with investigator-selected treatment by Day 28, supporting its role as an additional option for this specific patient population.
Although the findings are encouraging, Hovilpri is not a cure for HSV and is not approved for all HSV infections. Careful patient selection, consideration of drug interactions, and professional medical supervision remain essential.
As research continues, Hovilpri may help expand the available treatment options for patients facing persistent and difficult-to-treat HSV disease.
Sources
- Asahi Kasei Therapeutics, Inc. FDA approval announcement for Hovilpri (pritelivir), October 10, 2026.
- Hovilpri (pritelivir) Prescribing Information. Asahi Kasei Therapeutics, Inc., 2026.
- Birkmann A, et al. Journal of Medicinal Chemistry. 2022;65(20):13614-13628.
- Papanicolaou GA, et al. PRIOH-1 clinical trial findings presented at the Tandem Meetings, February 4-7, 2026.
- Shafat T, et al. Clinical Microbiology and Infection. 2025;31(5):761-772.
- Harfouche M, et al. Sexually Transmitted Infections. 2025;101(4):214-222.
Medical Disclaimer
This article is intended for general informational and educational purposes only. It does not constitute medical advice, diagnosis, or a recommendation to use any particular medicine. Treatment decisions should be made in consultation with a qualified healthcare professional who can assess an individual's medical history, current medicines, and clinical circumstances. Hovilpri is indicated for a specific group of immunocompromised adults with refractory mucocutaneous HSV lesions. It is not a cure for herpes simplex virus infection. Always consult the current official prescribing information for complete safety and prescribing details.